The most common side effect is nausea, followed by diarrhea
The FDA has approved semaglutide specifically for chronic weight management in non-diabetic adults with obesity or overweight status
doi: 10.3389/fimmu.2025.1578940 Received 18 February 2025 Accepted 24 March 2025 Published 10 April 2025 Volume 16 - 2025 Edited by Fabrizio Fontana, University of Milan, Italy Reviewed by Bjrn Steen Sklhegg, University of Oslo, Norway Josephine Anthony, Meenakshi Academy of Higher Education and Research, India Updates Copyright 2025 Fang, Gao, Jiang, Li and Li
Growth hormone plays a key role in regulating metabolism, supporting fat breakdown, and maintaining lean muscle mass
Lyon, France: International Agency for Research on Cancer, 2024